About the Journal

SKIN is a peer-reviewed, open access, online only journal dedicated to providing free access globally to disseminate dermatological knowledge. Authors retain copyright in their articles, licensing publication of their content through use of Creative Commons CCBY license. The journal does not charge fees, and is supported by the National Society for Cutaneous Medicine. 

Read More

Current Issue

Vol. 7 No. 6 (2023): November 2023 Issue

Published: 2023-11-13

In-Depth Reviews

A Comparative Outcomes Analysis: The Evolution and Growth of a Teledermatology Program to Accommodate High Patient Volumes

Leandra Doan, Marit Kreidel, MD, Jeffrey Benabio, MD, MBA, Gabriel Hernandez, BS, Walt Engler, BS, Linda Tolbert, MD, JD, EdD, MPH

Page 1090-1096

Original Research

Mohs Appropriate Use Criteria Scores and Treatment of Keratinocyte Carcinoma: Review of 11,145 Tumors

Richard H. Hope, Travis S. Dowdle, Landon Hope, Corley Pruneda

Page 1097-1107

Utility of Preoperative Staging for Clinically Localized Merkel Cell Carcinoma

Natalie Garcia, Victoria Jiminez, Zoey Duncan, Tanya Correya, Chimaraije Amu-Nnadi, Kristy Broman

Page 1108-1116

Research Letters

Blood Pressure Monitoring for Minoxidil Therapy in Alopecia Patients

Colin Kincaid, Justin Arnold, Celine Phone, Minjun Park, Arash Babadjouni, Natasha Mesinkovska

Page 1123-1125


Conference Proceedings

Brief Articles

Suspected Role of Long-term Anticonvulsant Use in the Development of Squamous Cell Carcinoma

Parastou Shahzeidi, Christopher Downing M.D., Armand B. Cognetta M.D.

Page 1150-1154

A Rare Case of Vasculitis Induced by Crusted Scabies Infection

Catherine Lyons, BS, BA, Lydia A. Luu, MD, Seth M. Martin, MD, Olivia L. Schenck, MD

Page 1155-1160

Comparing Porocarcinoma Outcomes Following Resection by Surgical Management Technique

Chelsea Shope, Laura Andrews, India Robinson-Pirotte, Jessica Forcucci

Page 1161-1164

Erythematous Plaque on Right Ear with Extension to Face and Neck in an Older Adult Male

Mara Trifoi, Norhan Shamloul, Bryan Anderson, Ryan Svoboda

Page 1165-1169

Cellular Deconvolution Reveals Unique Findings in Several Cell Type Fractions Within the Basal Cell Carcinoma Tumor Microenvironment

Michael Diaz, Jasmine Tran, Nicole Natarelli, Akash Sureshkumar, Mahtab Forouzandeh

Page 1170-1173

Coexistence of Granuloma Annulare and Castleman’s Disease: A Case Report

Lacey Falgout, Bonnie A Hodge, Tiffany T Mayo

Page 1174-1176

Successful Treatment of Unilateral Hailey-Hailey Disease

Angelica Zambrano, Fabiola Ramirez, Adrian Guevara , Trace Worrell

Page 1181-1185

Cutaneous Angioneurofibroma: A Vascularized Histopathologic Variant of Neurofibroma

Grant Zhao, Zachary J Solomon, Sharlene H See, Cuong V Nguyen

Page 1186-1190

Non-Pigmenting Fixed Drug Eruption Due to Fluconazole Without Cross-Reactivity to Itraconazole

Timea Kovacs, Christopher Davidson, Kacey Gibson, D.O., Jennifer Richardson

Page 1191-1194

Squamous Cell Carcinoma Arising in a Nevus Sebaceus in a 10-Year-Old Male

Hannah Porter, Rebecca Lapides, Keith Morley, Laura Greene, Chin Ho

Page 1199-1203

Methotrexate Monitoring in Dermatology: A Follow-Up Retrospective Cohort Study

Erica Mark, Stephany Vittitow, Alina Zufall, Joseph Nguyen, R. Hal Flowers

Page 1204-1207

Short Communications

Beyond Acne Vulgaris: Role of Cutibacterium Acnes in Atopic Dermatitis and Psoriasis

Maxwell Green, Nadia Kashetsky, Aileen Feschuk, Howard Maibach

Page 1208-1210

SKINmages: Clinical Images in Dermatology

Acquired Haemophilia A Associated with Bullous Pemphigoid

Sophie Evans, Jake Moss, Hannah Wainman

Page 1211-1213

Exophytic, Pedunculated, Yellow-Orange Nodules on the Elbows

Fareen Momin, Ayezel Munoz, Kathleen Kroger

Page 1214-1215

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

Management and Treatment Patterns in Psoriasis and Psoriatic Arthritis

Rola Gharib, Marc Bénard, Zuzana Mohrova, Amelia Boehme, Chao Song, Silky Beaty, Suzanne Gharib

Page s229

A US Claims Database Analysis Estimating Risk of All-Cause Mortality in Patients with Generalized Pustular Psoriasis

Alice Gottlieb, Thomas Zimmermann, Layla Lavasani, Juan Semeco, Mark Lebwohl

Page s230

Efficacy of Secukinumab in Patients With Mild to Moderate Psoriasis: A Pooled Analysis of 6 Phase 3 Studies

Bruce Strober, Peter van de Kerkhof, Heng Fan, Eugenia Levi, Andrew Blauvelt

Page s231

6-Month Real World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry

Mark Lebwohl, Bruce Strober, Amy Schrader, Alvin Li, Thomas Eckmann, Baojin Zhu, William Malatestinic, Julie Birt, Meghan Feely, Andrew Blauvelt

Page s232

Early Real-World Description of Baseline Demographics and Clinical Characteristics of Patients with Plaque Psoriasis on Tapinarof Cream 1%

Janine Fournier, Aseel Bin Sawad, Erin Zwick, Mariola Vazquez, Doral Fredericks, Anna Tallman, Krithika Rajagopalan

Page s234

Efficacy of Tapinarof Cream 1% Once Daily for the Treatment of Mild to Severe Intertriginous Plaque Psoriasis

Howard Sofen, Stephen Tyring, Sandra Marchese Johnson, Scott Guenthner, Patrick Shannon, Philip M. Brown, Katherine Tillman, Nancy Fitzgerald, Brandon Kirsch, Anna Tallman

Page s235

Time to Onset of a Minimal Clinically Important Difference in DLQI with Guselkumab Treatment in VOYAGE 1

Nastaran Abbarin, Kim Papp, Richard Langley, David Adam, Vincent Ho, Laura Park-Wyllie, Megan Miller, Yin You, Ya-Wen Yang, Melinda Gooderham

Page s236

PASI Improvement in the First 12 weeks from the Phase 3 VOYAGE 1, VOYAGE 2, ORION and ECLIPSE Guselkumab Clinical Trials

Nastaran Abbarin, Kim Papp, Ronald Vender, Richard Langley, Vincent Ho, Laura Park-Wyllie, Megan Miller, Yin You, Ya-Wen Yang

Page s237

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI)

Jeffrey M. Sobell, Boni Elewski, Subhashis Banerjee, Eugene Balagula, Thomas Scharnitz, Victoria Berger, Kim Hoyt, Paul Yamauchi, Miriam Bettencourt, Michael C. Cameron, Mark Lebwohl

Page s238

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial

Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Christopher EM Griffiths

Page s239

Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Mamitaro Ohtsuki, Lynda Spelman, Thierry Passeron, Kim A. Papp, Renata M. Kisa, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Bruce Strober, Diamant Thaçi, Andrew Blauvelt

Page s240

Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Bruce Strober, Howard Sofen, Shinichi Imafuku, Carle Paul, Melinda Gooderham, Lynda Spelman, Seong Jun Seo, Thierry Passeron, Renata M. Kisa, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Matthias Augustin, Linda Stein Gold, Andrew Alexis, Diamant Thaçi, Andrew Blauvelt, Mark Lebwohl

Page s241

Tapinarof Cream 1% Once Daily Improves Patient-reported Outcomes in the Treatment of Mild to Severe Intertriginous Plaque Psoriasis

Howard Sofen, Stephen Tyring, Sandra Marchese Johnson, Scott Guenthner, Patrick Shannon, Philip M. Brown, Katherine Tillman, Nancy Fitzgerald, Brandon Kirsch, Anna Tallman

Page s242

Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

Diamant Thaçi, Mark Lebwohl, Richard B. Warren, Leon Kircik, Subhashis Banerjee, Andrew Napoli, Renata M. Kisa, Misti Linaberry, Kim Hoyt, Andrew Blauvelt

Page s243

Effect of Subcutaneous Spesolimab on the Prevention of Generalized Pustular Psoriasis Flares Over 48 weeks: Subgroup Analyses from the Effisayil 2 Trial

Richard Warren, David Burden, Siew Eng Choon, Kenneth Gordon, Lluis Puig, Arash Mostaghimi, Georgios Kokolakis, Na Hu, Patrick Hofmann, Christian Thoma, Milan Anadkat

Page s245

Flare Frequency and Duration in Patients with Generalized Pustular Psoriasis (GPP)

Denis Jullien, Affandi Azura, Laurent Misery, Tang Jyh Jong, Haminda Turki, Pubalan Muniandy, Wooi Chiang Tan

Page s246

Effect of Spesolimab on Achieving Sustained Disease Remission in Patients with Generalized Pustular Psoriasis: Results from the Effisayil 2 Study

Kenneth Gordon, Curdin Conrad, Mark Lebwohl, Jonathan Barker, Tsen-Fang Tsai, Joseph Merola, Curdin Conrad, Min Zheng, Na Hu, Patrick Hofmann, Christian Thoma, Kilian Eyerich

Page s247

Real-World Switch Rates for Patients With Psoriasis Initiating Risankizumab Stratified by Body Mass Index

Jashin Wu, Manish Patel, Huzefa Photowala, Chao Li, April Armstrong

Page s248

Maintenance of Response to Risankizumab in Patients With Psoriatic Arthritis: A 3-year Analysis of the KEEPsAKE 1 and 2 Trials

Andrew Ostor, Michael Chen, Byron Padilla, Cuiyong Yue, Huzefa Photowala, Jonathon Rocco, Joseph Merola

Page s249

Long-term Safety of Apremilast From a Pooled Analysis of 15 Randomized, Placebo-controlled Studies of Psoriasis, Psoriatic Arthritis, and Oral Ulcers Associated With Behçet’s Syndrome

Philip J. Mease, Gülen Hatemi, Maria Paris, Sue Cheng, Peter Maes, Wendy Zhang, Rebecca Shi, Andrea Flower, Linda Stein Gold; Dawn Nicewarner

Page s250

Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis

Christopher Bunick, Neal Bhatia, James Del Rosso, Zoe Draelos, Lawrence Eichnfield, Leon Kircik, Mark Lebwohl, Melinda Gooderham, Lawrence Green, Adelaide Hebert, Ronald Vender, Matthew Zirwas, Eric Simpson, Linda Stein Gold, Melissa Seal, Scott Snyder, David Osborne, Patrick Burnett, Robert Higham, David Chu, David Berk

Page s251

Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis: Individual Patient Response From the Pooled DERMIS-1 and DERMIS-2 Phase 3 Trials

James Del Rosso, H. Chih-ho Hong, Leon Kircik, Melinda Gooderham, Mark Lebwohl, Kim Papp, Linda Stein Gold, Adelaide Hebert, Melissa Seal, David Krupa, David Chu, Patrick Burnett, David Berk, Robert Higham

Page s252

How Labeling Warnings and Precautions May Impact the Proportion of Psoriasis Patients Initiating New Treatments

Richard Langley, Shauna Jardon, Jennifer Montgomery, Kate K. Orroth, Cynthia Deignan, Mark Lebwohl; Dawn Nicewarner

Page s253

Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study

Loretta Fiorillo, Emily Becker, Raul de Lucas, Anna Belloni-Fortina, Peter Maes, Rajneet K. Oberoi, Maria Paris, Wendy Zhang, Zuoshun Zhang, Lisa Arkin; Dawn Nicewarner

Page s254

Efficacy of Apremilast in Patients with Moderate-to-Severe Genital Psoriasis: Body Surface Area Subgroup Results from the Phase 3 DISCREET Trial

Joseph F. Merola, Lawrence Charles Parish, Lyn Guenther, Charles Lynde, Jean-Philippe Lacour, Petra Staubach, Sue Cheng, Cynthia Deignan, Mindy Chen, Kim A. Papp; Dawn Nicewarner

Page s255

A Phase 3b Study Evaluating Safety and Efficacy of Risankizumab in Adult Patients with Moderate-to-Severe Plaque Psoriasis with Palmoplantar (Non-Pustular) Involvement

Mark Lebwohl, Michael Bukhalo, Linda Stein Gold, Michelle Pelle, Bradley Glick, Mar Llamas-Velasco, Samuel Sanchez-Rivera, Tianyu Zhan, Leonidas Drogaris, Kevin Douglas, Greg St. John, Ramon Espaillat, Robert Bissonnette

Page s256

Efficacy and Safety of Risankizumab Compared with Apremilast in Patients with Moderate Plaque Psoriasis: Mean PASI and BSA Results From the Phase 4 IMMpulse Trial

Linda Stein Gold, Jerry Bagel, Stephen Keith Tyring, Chih-ho Hong, Lev Pavlovsky, Andreas Pinter, Adam Reich, Leonidas Drogaris, Tianshuang Wu, Huzefa Photowala, Vassilis Stakias, Sven Richter, Kim Papp

Page s257

Skin Cancer

Clinical and Histological Clearance of VP-315: Exploratory Results of an Investigational Non-surgical Immunotherapy in Subjects with Biopsy Proven Basal Cell Carcinoma

Neal Bhatia, MD, Jon Kantor, MD, Lawrence Green, MD, Jonathon Weiss, MD, Cynthia Wilson, RN, BSN, Susan Cutler, DMD, Jayson Rieger, PhD, MBA, David K. Glover, ME, PhD, Pamela Rumney, RN, CCRC, Gary Goldenberg, MD

Page s259

Results from Part 1 Safety Run-in Period of a 2-part, Phase 2, Multicenter, Open-label, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Subjects with Basal Cell Carcinoma

Neal Bhatia, MD, Jonathon Kantor, MD, Lawrence Green, MD, Jonathon Weiss, MD, Cynthia Wilson, RN, BSN, Susan Cutler, DMD, Jayson Rieger, PhD, MBA, David K. Glover, ME, PhD, Pamela Rumney, RN, CCRC, Gary Goldenberg, MD

Page s260

Patient- and Clinician-Reported Outcomes of Tirbanibulin 1% in the Treatment of Actinic Keratosis on the Face and Scalp (PROAK Study)

Todd Schlesinger, April Armstrong, Vishal A. Patel, Leon Kircik, Brian Berman, Neal Bhatia, Mark Lebwohl, Darrell Rigel, Siva Narayanan, Volker Koscielny, Ismail Kasujee, James Del Rosso

Page s262

Safety and Tolerability of Tirbanibulin 1% Treatment of Actinic Keratosis on Face and Scalp in Routine Clinical Practice Across the U.S. (PROAK Study)

Todd Schlesinger, Mark Lebwohl, James Del Rosso, Vishal A. Patel, Leon Kircik, April Armstrong, Brian Berman, Darrell Rigel, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Neal Bhatia

Page s263

Safety, Tolerability and Efficacy of Tirbanibulin Ointment 1% Treatment on 100 cm2 of the Face and Scalp in Patients with Actinic Keratosis: A Phase 3 Study

Neal Bhatia, Andrew Blauvelt, Edward Lain, Abel Jarell, Janet DuBois, Maria Luisa Tamarit, Meritxell Falqués, Vera Kiyasova, Laura Padullés, Raquel Otero

Page s264


Performance of the 23-gene Expression Profile (23-GEP) Test by Histopathological Evaluation in an Independent, Multi-Center Performance Cohort of Cutaneous Melanocytic Neoplasms

Matthew S. Goldberg, Kiran Motaparthi, Gregory A. Hosler, Clay J. Cockerell, Sarah I. Estrada, Natalie D. Depcik-Smith, Jose A. Plaza

Page s265

Genomics and Precision Medicine

Gene Expression Differences Identified in Skin Samples of Early-Stage Mycosis Fungoides, Atopic Dermatitis, and Psoriasis

Aaron Farberg, Matthew Goldberg, Ann Quick, Olga Zolochevska, Jeff Wilkinson, Jonathan Silverberg, Peter Lio, John Koo, Jeffrey Weinberg, Mark Lebwohl

Page s267


Aesthetic Efficacy of a Novel Topical Combination Brightening Regimen to Treat Facial Hyperpigmentation

Lisa T. Goberdhan, MSHS, Katie Schneider, BS, Arielle Bautista, BS, Elizabeth T. Makino, BS, CCRA, MBA, Rahul C. Mehta, PhD

Page s268

Atopic Dermatitis

Improvements in Quality of Life and Itch Symptoms with Dupilumab in Patients with Atopic Dermatitis: A Targeted Literature Review and Meta-Analysis of Real-World Studies

Marjolein de Bruin-Weller, Jonathan Silverberg, Debra Sierka, Bruno Martins, Min Yang, Molly Frean, Patricia Guyot, Kerry Noonan, Zhixiao Wang, Gaëlle Bégo-Le-Bagousse

Page s270

Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis

Emma Guttman-Yassky, Stephan Weidinger, Eric Simpson, Melinda Gooderham, Alan Irvine, Lynda Spelman, Jonathan Silverberg, Hany Elmaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Chaoran Hu, Fan Emily Yang, Evangeline Pierce, Laia Bardolet, Diamant Thaci

Page s271

Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo

Jenny E. Murase, Monica Munera-Campos, H. Chih-ho Hong, Alain Taieb, Wen-Hung Chung, Amber Reck Atwater, Maria Jose Rueda, Jinglin Zhong, Maria Lucia Buziqui Piruzeli, Ignasi Pau-Charles, Mette Deleuran

Page s272

Lebrikizumab Delivers Clinically Meaningful and Continuous Improvement in Itch-Free Days in Atopic Dermatitis Through One Year

Gil Yosipovitch, Claudia Zeidler, Christian J. Apfelbacher, Vivian Laquer, Brian S. Kim, Marta Casillas, Evangeline Pierce, Sherry Chen, Meihua Qiao, Helena Agell, James Del Rosso

Page s273

Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity

Linda Stein Gold, Kilian Eyerich, Howard Sofen, Pedro Herranz, Leon Kircik, Tony Bewley, Eric Wolf, Gaia Gallo, Yuxin Ding, Fan Emily Yang, Ignasi Pau-Charles, Melinda Gooderham

Page s274

Patient-Level, Visit-by-Visit Data Highlight the Extent of Skin and Itch Improvement in Atopic Dermatitis With Lebrikizumab

Jonathan Silverberg, Leon Kircik, Melinda Gooderham, Gaia Gallo, Eric Wolf, Helena Agell, Fan Emily Yang, Yuxin Ding, Eric Simpson

Page s275

Conjunctivitis Does Not Increase With Longer Duration of Lebrikizumab Exposure in Patients With Moderate-to-Severe Atopic Dermatitis

April Armstrong, Andreas Wollenberg, Marjolein de Bruin-Weller, Peter A. Lio, Chitra R. Natalie, Fangyi Zhao, Amber Reck Atwater, Gemma Jimenez, Chia-Yu Chu, Christian Vestergaard

Page s276

Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy

Natasha Atanaskova , Maryanne Senna, Arash Mostaghimi, Julien Seneschal, Amy McMichael, Najwa Somani, Na Lu, Jianxiang Zou, Jakub Jedynak, Hitoe Torisu-Itakura, Jerry Shapiro

Page s277

Lebrikizumab Provides Progressive Improvements in Skin Clearance and Itch Relief Over One Year in Patients with Atopic Dermatitis

April Armstrong, Kamran Ghoreschi, David Rosmarin, Todd Schlesinger, Alan Irvine, Anthony Bewley, Marta Casillas, Gaia Gallo, Yuxin Ding, Chenjia Xu, Ignasi Pau-Charles, Eric Simpson

Page s278

Lebrikizumab Provides Rapid Response in EASI Components and Itch in Moderate-to-Severe Atopic Dermatitis

Eric Simpson, Gil Yosipovitch, Kilian Eyerich, Delphine Staumont-Sallé, Mona Shahriari, Gaia Gallo, Eric Wolf, Evangeline Pierce, Chunyuan Liu, Jinglin Zhong, Helena Agell, Marjolein de Bruin-Weller

Page s279

Tapinarof Cream 1% Once Daily for the Treatment of Extensive Atopic Dermatitis in Adolescents and Children: Outcomes from the 4-Week Maximal Usage Trial

Amy Paller, Adelaide A. Hebert, Philip M. Brown, Victoria Butners, Nancy Fitzgerald, Mercedes E. Gonzalez, Stephen C. Piscitelli

Page s280

Rapid and Early Onset of Itch Relief with Tapinarof Cream 1% Once Daily in Two Pivotal Phase 3 Trials in Adults and Children Down to Two Years of Age with Atopic Dermatitis

Eric Simpson, Jonathan I. Silverberg, Robert Bissonnette, Linda Stein Gold, April Armstrong, Adelaide A. Hebert, Rocco T. Serrao, Jeannette R. Jakus, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli, Anna Tallman, Lawrence F. Eichenfield

Page s281

Lebrikizumab Provides Stable Itch Response With No or Minimal Fluctuations up to One Year in Patients With Atopic Dermatitis

James Del Rosso, Gil Yosipovitch, Sonja Ständer, Jonathan Silverberg, Andreas Wollenberg, Peter A. Lio, Jose Manuel Carrascosa, Gaia Gallo, Marta Casillas, Evangeline Pierce, Yuxin Ding, Zhenhui Xu, Helena Agell, Linda Stein Gold

Page s282

Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Atopic Dermatitis in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age

Jonathan I. Silverberg, Lawrence F. Eichenfield, Adelaide A. Hebert, Eric Simpson, Linda Stein Gold, Robert Bissonnette, Kim A. Papp, John Browning, Pearl Kwong, Neil J. Korman, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli, Matthew C. Somerville, Anna Tallman, Leon Kircik

Page s283

Patient Preferences in Moderate-to-Severe Atopic Dermatitis (AD): A Discrete Choice Experiment (DCE)

Steven R. Feldman, Annie Guerin, Marjolaine Gauthier-Loiselle, Ami J Claxton, Nisha C Hazra, Yan Meng, Kirsten Gallant, Sanjeev Balu

Page s284

Clinical Burden and Impairment in Moderate-to-Severe Atopic Dermatitis

Nisha Hazra, Steven R. Feldman, Annie Guerin, Marjolaine Gauthier-Loiselle, Ami J Claxton, Yan Meng, Kirsten Gallant, Sanjeev Balu

Page s285

Hidradenitis Suppurativa

Spesolimab for Hidradenitis Suppurativa: A Proof-of-Concept Study

Afsaneh Alavi, Errol Prens, Alexa Kimball, James Krueger, Sutirtha Mukhopadhyay, Hui Wang, Nathalie Ivanhoff, Ana Cristina Hernandez, Christos Zouboulis

Page s286


Acne & Rosacea

A Systematic Literature Review and Network Meta-Analysis of Comparative Efficacy of Topical Fixed-Dose Combination Treatments for Moderate to Severe Acne Vulgaris

Julie C Harper, Hilary E Baldwin, Saswata Paul Choudhury, Bikramaditya Ghosh, Deepti Rai, Md Sohail Aman, Abhra Roy Choudhury, Debalina Dey , Sekhar K Dutta, Subrata Bhattacharyya, Tina Lin, George Joseph, Ankur A Dashputre, Jerry Tan

Page s290


Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program

Brett King, Jennifer Soung, Christos Tziotzios, Lidia Rudnicka, Pascal Joly, Melinda Gooderham, Rodney Sinclair, Susan D. Anway, Dalia Wajsbrot, Alexandre Lejeune, Samuel H. Zwillich

Page s291

Impact of Previous Alopecia Areata Treatment on Efficacy Responses After 24 and 48 Weeks of Treatment With Ritlecitinib

Jennifer Fu, Alexander Egeberg, Susan Holmes, Sergio Vano-Galvan, Martin Steinhoff, Roger Edwards, Ranjit Nagra, Robert Wolk, Helen Tran, Ernest Law

Page s292

Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study

Melissa Piliang, Charles Lynde, Brett King, Paradi Mirmirani, Rodney Sinclair, Robert Wolk, Samuel Zwillich, Helen Tran, Fan Zhang, Liza Takiya

Page s293

Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies

Jennifer Soung, Brett King, Christos Tziotzios, Lidia Rudnicka, Pascal Joly, Melinda Gooderham, Rodney Sinclair, Dalia Wajsbrot, Helen Tran, Robert Wolk

Page s294

Agreement Between Patient and Physician Assessment of Eyebrow and Eyelash Hair Loss in Two Phase 3 Trials Evaluating Baricitinib in Patients with Severe Alopecia Areata

Justin Ko, Amy McMichael, Antonella Tosti, Taisuke Ito, Yves Dutronc, Guanglei Yu, Yunfei Chen, Mwangi Murage, Chiara Chiasserini, Arash Mostaghimi

Page s295

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2

Brett King, Manabu Ohyama, Maryanne Senna, Jerry Shapiro, Yves Dutronc, Jill Kolodsick, Guanglei Yu, Chunyuan Liu, Chiara Chiasserini, Bianca Maria Piraccini

Page s296

Baricitinib Treatment Increases Eyebrow and Eyelash ​Regrowth Up to ​52 Weeks

Arash Mostaghimi, Melissa Piliang, Charles Lynde, Jacek C. Szepietowski, Jakub P. Jedynak, Najwa Somani, Na Lu, Guanglei Yu, Chiara Chiasserini, Maria Hordinsky

Page s297

Pruritus & Prurigo Nodularis

Anxiety and Depression in Patients with Prurigo Nodularis: Results from the PN – Patient Reported Burden of Sickness (PN-TREK) Study

Shawn G Kwatra, Bruno Martins, Min Yang, Abigail Zion, Joseph Zahn, Bengisu Ozarslan, Donia Bahloul, Ryan B Thomas

Page s298



Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Analysis of Mental Health and Associated Disorders

Andrew Blauvelt, April Armstrong, Joseph F. Merola, Bruce Strober, Dirk de Cuyper, Luke Peterson, Owen Davies, Jeffrey L. Stark, Mark Lebwohl

Page s300

View All Issues